Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) EBITDA (2022 - 2025)

BioXcel Therapeutics has reported EBITDA over the past 4 years, most recently at -$10.3 million for Q4 2025.

  • Quarterly results put EBITDA at -$10.3 million for Q4 2025, up 2.01% from a year ago — trailing twelve months through Dec 2025 was -$50.5 million (up 24.96% YoY), and the annual figure for FY2025 was -$50.5 million, up 24.96%.
  • EBITDA for Q4 2025 was -$10.3 million at BioXcel Therapeutics, up from -$14.2 million in the prior quarter.
  • Over the last five years, EBITDA for BTAI hit a ceiling of -$10.1 million in Q1 2025 and a floor of -$52.9 million in Q4 2022.
  • Median EBITDA over the past 4 years was -$22.0 million (2023), compared with a mean of -$28.1 million.
  • Biggest five-year swings in EBITDA: plummeted 62.64% in 2023 and later skyrocketed 68.34% in 2024.
  • BioXcel Therapeutics' EBITDA stood at -$52.9 million in 2022, then surged by 62.42% to -$19.9 million in 2023, then skyrocketed by 47.21% to -$10.5 million in 2024, then grew by 2.01% to -$10.3 million in 2025.
  • The last three reported values for EBITDA were -$10.3 million (Q4 2025), -$14.2 million (Q3 2025), and -$15.9 million (Q2 2025) per Business Quant data.